Dr.ย Salomonย Stemmer
MD (Doctor of Medicine)
Head, Oncology Division โ Davidoff Cancer Center
corporate_fareRabin Medical Center (Beilinson Campus), Petah Tikva
Salomon Stemmer
MD (Doctor of Medicine)
Prof. Salomon M. Stemmer is a senior professor of oncology and Head of the Oncology Division at the Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel, affiliated with the Sackler Faculty of Medicine at Tel Aviv University. He brings over 25 years of clinical and research experience to the management of breast cancer, ovarian cancer, and other solid tumours.
Prof. Stemmer is internationally recognised for his work in personalised breast cancer treatment, particularly his leadership in Recurrence Score-guided therapy using the Oncotype DX assay. He has led and published findings from one of the largest prospectively designed national registries evaluating genomic risk-guided treatment decisions in early-stage hormone receptor-positive breast cancer. As head of the Charles E. Trobman Oncology Data Management Center at the Davidoff Center, he has built a research infrastructure supporting real-world evidence, clinical trials, and translational oncology studies. His publication record spans over 189 peer-reviewed papers with an h-index of 43, and his work has been cited over 9,600 times in the scientific literature. Patients and families worldwide consult Prof. Stemmer for expert second opinions and treatment planning in complex breast cancer and ovarian cancer cases.
Why Consider Prof. Salomon Stemmer?
Prof. Stemmer is one of Israel's most cited oncologists, combining deep clinical experience in breast and ovarian cancer with a research-driven, personalised treatment approach rooted in molecular and genomic data.
Areas of Specialisation
Personalised oncology for breast cancer, ovarian cancer, and solid tumours guided by molecular diagnostics and real-world clinical evidence
Prof. Stemmer's clinical specialisation centres on breast cancer and ovarian cancer, combining evidence-based systemic therapy with precision oncology tools such as genomic risk assays and molecular profiling.
Breast Cancer Oncology
Comprehensive medical oncology for early, locally advanced, and metastatic breast cancer, incorporating genomic risk assessment and personalised treatment planning.
- arrow_rightGenomic risk assessment using the Oncotype DX 21-gene assay
- arrow_rightChemotherapy decision-making for ER-positive, HER2-negative early breast cancer
- arrow_rightEvidence from prospectively designed national registry studies
- arrow_rightChemotherapy regimen planning for early and advanced breast cancer
- arrow_rightHormonal and endocrine therapy for hormone receptor-positive disease
- arrow_rightHER2-targeted therapy and CDK4/6 inhibitor-based regimens
- arrow_rightTreatment planning for triple-negative breast cancer
- arrow_rightSystemic treatment planning for metastatic disease
- arrow_rightTargeted therapy based on molecular tumour profile
- arrow_rightClinical trial evaluation for eligible patients
Ovarian Cancer and Gynaecologic Oncology
Medical oncology management of ovarian cancer and related gynaecologic malignancies, including BRCA-guided treatment and maintenance therapy planning.
- arrow_rightChemotherapy planning for newly diagnosed and recurrent ovarian cancer
- arrow_rightMaintenance therapy with PARP inhibitors for BRCA-mutated disease
- arrow_rightPlatinum-sensitive and platinum-resistant disease management
- arrow_rightBRCA1/2 and homologous recombination deficiency testing guidance
- arrow_rightMolecular profiling to guide targeted therapy selection
- arrow_rightClinical trial matching for ovarian cancer patients
Procedures & Clinical Services
Medical oncology services for breast cancer, ovarian cancer, and personalised treatment planning
Prof. Stemmer provides medical oncology consultations, systemic treatment planning, genomic risk evaluation, and clinical trial coordination for patients with breast and ovarian cancer.
Breast Cancer Systemic Treatment
Medical OncologyPersonalised systemic therapy planning for early, locally advanced, and metastatic breast cancer incorporating genomic and molecular data.
Genomic-Guided Treatment Planning
Targeted TherapyMolecular and genomic risk assessment to personalise chemotherapy decisions in early-stage breast cancer.
Ovarian Cancer Medical Oncology
Medical OncologySystemic treatment planning and maintenance therapy management for ovarian and gynaecologic cancers.
Second Opinion and Complex Case Review
Second OpinionStructured expert review for patients with complex breast or ovarian cancer treatment decisions, recurrent disease, or unclear chemotherapy benefit.
Research & Publications
Leading contributions to breast cancer genomics, real-world oncology outcomes, and clinical trial research
Prof. Stemmer has authored and co-authored over 189 peer-reviewed publications with an h-index of 43. His work spans breast cancer genomics, ovarian cancer, real-world registry studies, clinical trials, infectious complications in cancer patients, and COVID-19 outcomes in oncology populations.
Prof. Stemmer's full publication list is available on PubMed and Google Scholar. His work has received over 9,600 citations with an h-index of 43.
Education & Training
Prof. Stemmer completed his medical training and oncology specialisation in Israel and has held academic affiliation with Tel Aviv University and the University of New South Wales.
Clinical Experience
Prof. Stemmer has built his career at Rabin Medical Center and the Davidoff Cancer Center, progressing from clinician and researcher to Head of the Oncology Division and director of one of Israel's leading oncology data and research programmes.
Languages & International
Prof. Stemmer consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients who require assistance in languages beyond English and Hebrew.
CancerFax can coordinate professional medical interpreter support for international patients consulting in other languages.
How CancerFax Helps You Access Dr. Salomon Stemmer
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Salomon Stemmer's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Salomon Stemmer's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Salomon Stemmer before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Salomon Stemmer's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Salomon Stemmer's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Salomon Stemmer's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Salomon Stemmer
Prof. Salomon M. Stemmer is a senior professor of oncology and Head of the Oncology Division at the Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. He is affiliated with Tel Aviv University and is internationally recognised for his expertise in breast cancer, ovarian cancer, personalised oncology, and genomic risk-guided treatment.
Prof. Stemmer specialises in breast cancer and ovarian cancer. His clinical focus includes early-stage and metastatic breast cancer, hormone receptor-positive disease, HER2-positive breast cancer, triple-negative breast cancer, and ovarian cancer including BRCA-mutated disease. He also evaluates selected solid tumours requiring systemic therapy or expert review.
Prof. Stemmer has been a leading investigator in national registry studies evaluating the use of the Oncotype DX Recurrence Score assay to guide chemotherapy decisions in early-stage, ER-positive, HER2-negative breast cancer. His published research has helped define which patients may safely avoid adjuvant chemotherapy and which patients benefit from it, contributing to personalised treatment decisions in oncology practice worldwide.
International patients may submit a second-opinion request through CancerFax. The CancerFax team will review your medical documents including pathology reports, imaging, molecular test results, and treatment history, prepare a structured case summary, and coordinate the submission to the Davidoff Cancer Center, subject to availability and institutional acceptance.
Upload your medical reports through the CancerFax platform. Our team will review the documents, prepare a structured case file, and coordinate the next steps with Rabin Medical Center or the Davidoff Cancer Center on your behalf. Please include your histopathology report, ER/PR/HER2 status, imaging reports, genomic test results if available, and previous treatment details.
Patients should ideally prepare the following before consultation: histopathology and immunohistochemistry reports, ER/PR/HER2/Ki-67 status for breast cancer, BRCA or genetic testing results if available, PET-CT, CT, MRI, mammography or ultrasound reports, tumour marker results such as CA-125 or CA 15-3, previous chemotherapy and targeted therapy details, surgery and radiation therapy summaries, Recurrence Score or molecular profiling reports if available, and a current medication list.
Connect with Salomon Stemmer Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.